Kaituo Pharmaceutical-B announced that its self-developed long-term human safety test for KT-939, a novel high-efficiency tyrosinase inhibitor that inhibits melanin production, was successfully completed on September 4, 2026. After a total of 114 subjects used KT-939 for 52 consecutive weeks, preliminary data showed that there were no adverse skin reactions, and clinical use results for 28 weeks in the middle of the trial were consistent, fully demonstrating that KT-939 has good safety. This long-term safety test is an open-label, single-arm, single-center study to assess the potential for adverse human skin reactions caused by long-term topical use of cosmetics containing KT-939 ingredients. It mainly focuses on the safety of 0.2% KT-939 on the skin when applied topically for 52 weeks. The company is actively promoting the registration application process for KT-939. After obtaining the results of this long-term safety test, it plans to complete the submission of all application materials to the Drug Administration as soon as possible.

Kaituo Pharmaceutical-B announced that its self-developed long-term human safety test for KT-939, a novel high-efficiency tyrosinase inhibitor that inhibits melanin production, was successfully completed on September 4, 2026. After a total of 114 subjects used KT-939 for 52 consecutive weeks, preliminary data showed that there were no adverse skin reactions, and clinical use results for 28 weeks in the middle of the trial were consistent, fully demonstrating that KT-939 has good safety. This long-term safety test is an open-label, single-arm, single-center study aimed at evaluating the potential for adverse human skin reactions caused by long-term topical use of cosmetics containing KT-939 ingredients. It mainly focuses on the safety of 0.2% KT-939 on the skin when applied topically for 52 weeks. The company is actively promoting the registration application process for KT-939. After obtaining the results of this long-term safety test, it plans to complete the submission of all application materials to the Drug Administration as soon as possible.